48,466
edits
Difference between revisions of "Programmed death-ligand 1"
Jump to navigation
Jump to search
no edit summary
| Line 5: | Line 5: | ||
PD-L1 antibodies are being used to treat:<ref name=pmid26895815>{{Cite journal | last1 = Gandini | first1 = S. | last2 = Massi | first2 = D. | last3 = Mandalà | first3 = M. | title = PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. | journal = Crit Rev Oncol Hematol | volume = 100 | issue = | pages = 88-98 | month = Apr | year = 2016 | doi = 10.1016/j.critrevonc.2016.02.001 | PMID = 26895815 }}</ref> | PD-L1 antibodies are being used to treat:<ref name=pmid26895815>{{Cite journal | last1 = Gandini | first1 = S. | last2 = Massi | first2 = D. | last3 = Mandalà | first3 = M. | title = PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. | journal = Crit Rev Oncol Hematol | volume = 100 | issue = | pages = 88-98 | month = Apr | year = 2016 | doi = 10.1016/j.critrevonc.2016.02.001 | PMID = 26895815 }}</ref> | ||
*[[Malignant melanoma]]. | *[[Malignant melanoma]]. | ||
*[[ | *[[Non-small cell lung cancer]]. | ||
*[[Renal cell carcinoma]]. | *[[Renal cell carcinoma]]. | ||